Press releases
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
- Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
On Friday, Halozyme Therapeutics Inc (RV7:FRA) closed at 46.08, -4.10% below its 52-week high of 48.05, set on Jun 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 46.08 |
---|---|
High | 46.08 |
Low | 46.08 |
Bid | 46.21 |
Offer | 46.30 |
Previous close | 45.85 |
Average volume | 509.10 |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 20.48 |
Market cap | 6.30bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:07 BST.
More ▼